Advanced glycation end product (AGE) receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor
- 12 September 2006
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 103 (37), 13801-13806
- https://doi.org/10.1073/pnas.0600362103
Abstract
Advanced glycation end product receptors (AGERs) play distinct functional roles in both the toxicity and disposal of advanced glycation end products (AGEs), substances that are linked to diabetes and aging. Overexpression of AGER1 in murine mesangial cells (MCs) (MC-R1) inhibited AGE-induced MAPK1,2 phosphorylation and NF-κB activity and also increased AGE degradation. The mechanism of the inhibitory effects of AGER1, upstream of MAPK, was explored in MCs and HEK293 AGER1-expressing cells. AGE-induced Ras activation was found to be linked to Shc/Grb2 complex formation and Shc phosphorylation in MCs, responses that were markedly reduced in MC-R1 cells. AGE responses also included EGF receptor (EGFR) phosphorylation in MCs or HEK293 cells, but this link was blocked in both MC-R1 and HEK293-R1 cells. Coexpression of AGER1 and EGFR in HEK293 cells decreased AGE-mediated EGFR and p44/p42 phosphorylation but not EGF-induced p44/p42 activation. AGE, S100/calgranulin, or H2O2 promoted MAPK phosphorylation in EGFR+ cells in a manner that was inhibitable by an EGFR inhibitor, AG1478. Also, in AGER1 cells, AGE-induced H2O2 formation and AGE- or S100-induced p44/p42 phosphorylation were suppressed, and these effects were restored by R1 siRNA. These data confirm that R1 negatively regulates AGE-mediated oxidant stress-dependent signaling via the EGFR and Shc/Grb2/Ras pathway. AGER1 could serve as a model for developing therapeutic targets against vascular and kidney disorders related to diabetes and aging.Keywords
This publication has 42 references indexed in Scilit:
- Diabetes-Induced Renal Vascular Dysfunction Is Normalized by Inhibition of Epidermal Growth Factor Receptor Tyrosine KinaseJournal of Vascular Research, 2005
- Epidermal growth factor receptor tyrosine kinase‐mediated signalling contributes to diabetes‐induced vascular dysfunction in the mesenteric bedBritish Journal of Pharmacology, 2005
- Parathyroid Hormone Receptor Trafficking Contributes to the Activation of Extracellular Signal-regulated Kinases but Is Not Required for Regulation of cAMP SignalingPublished by Elsevier ,2005
- Protein Kinase C and Epidermal Growth Factor Stimulation of Raf1 Potentiates Adenylyl Cyclase Type 6 Activation in Intact CellsMolecular Pharmacology, 2004
- Phosphatidylinositol 3′-Kinase-dependent Activation of Renal Mesangial Cell Ki-Ras and ERK by Advanced Glycation End ProductsPublished by Elsevier ,2003
- Oxidative Stress-induced Phospholipase C-γ1 Activation Enhances Cell SurvivalJournal of Biological Chemistry, 2001
- Differential expression of renal AGE-receptor genes in NOD mice: Possible role in nonobese diabetic renal diseaseKidney International, 2000
- Shc Phosphotyrosine-Binding Domain Dominantly Interacts with Epidermal Growth Factor Receptors and Mediates Ras Activation in Intact CellsMolecular Endocrinology, 1998
- Protein glycation in the kidney: Role in diabetes and agingKidney International, 1996
- How receptor tyrosine kinases activate rasTrends in Biochemical Sciences, 1993